Evidence map›Paper›PMID 40663309›Full record

ArticleJournal of neuro-oncology2025

Glioblastoma in young adult patients: contemporary patterns of care and survival in the United States.

Ory Haisraely, Srivatsa Vedala, Areeba Al-Sharfeen, Gohar S Manzar, Subha Perni, Martin C Tom, Thomas H Beckham, Chenyang Wang, Debra N Yeboa, Caroline Chung and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ory HaisraelyDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Srivatsa VedalaDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Areeba Al-SharfeenDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gohar S ManzarDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Subha PerniDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Martin C TomDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Thomas H BeckhamDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chenyang WangDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Debra N YeboaDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Caroline ChungDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mary Frances McAleerDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Amol J GhiaDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chibawanye I EneDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shiao-Pei WeathersDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Susan L McGovernDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christine F WoganDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael RothDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jing LiDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Brian DeDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. BSDe@mdanderson.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGlioblastoma (GBM) is a highly aggressive brain tumor with poor outcomes, most commonly affecting older adults. Young adults (YA; ages 18–39), though less frequently affected, demonstrate distinct clinical and biological characteristics that may influence treatment response and survival. This study aimed to evaluate treatment patterns and outcomes in YA GBM relative to older adults in a national dataset.

methodsThis retrospective cohort analysis of the National Cancer Database (NCDB) from 2004 to 2021 identified GBM patients aged 18 years and older. Baseline demographics, tumor characteristics, and treatment patterns were compared between YAs and patients aged ≥ 40 years. Survival analysis was limited to isocitrate dehydrogenase (IDH)-wildtype GBM diagnosed in 2018 or later. Multivariable Cox regression was used to identify factors associated with overall survival (OS).

resultsOf 179,854 GBM patients, 6,941 (4.2%) were YAs. Compared with older adults, YAs were more likely to be non-White (19.9% vs. 10.8%), uninsured (5.9% vs. 2.2%), and treated at academic centers (75.9% vs. 68.0%). YAs more frequently underwent gross total resection (30.0% vs. 25.1%) and received the Stupp regimen (58.8% vs. 46.0%). Median OS time was significantly longer in YAs (25.8 vs. 11.4 months, p < 0.001), with 5-year survival probabilities of 30.6% for YAs vs. 5.0% for older adults. Multivariable analysis confirmed that YA status was independently associated with improved OS (hazard ratio = 0.43, p < 0.001).

conclusionYA GBM patients experience better survival and receive more aggressive treatment than older adults. These findings support the need for age-adapted therapeutic strategies and highlight the importance of integrating molecular profiling and survivorship planning in YA GBM care.

Indexed as

Brain NeoplasmsGlioblastomaAdolescentAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedRetrospective StudiesSurvival RateUnited StatesYoung Adult

Identifiers

PMID40663309

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.